Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)
3.820
-0.100 (-2.55%)
Jun 13, 2025, 2:45 PM CST
SHA:600664 Revenue
Harbin Pharmaceutical Group had revenue of 4.17B CNY in the quarter ending March 31, 2025, with 0.78% growth. This brings the company's revenue in the last twelve months to 16.21B, up 3.45% year-over-year. In the year 2024, Harbin Pharmaceutical Group had annual revenue of 16.18B with 4.65% growth.
Revenue (ttm)
16.21B
Revenue Growth
+3.45%
P/S Ratio
0.61
Revenue / Employee
1.59M
Employees
10,180
Market Cap
9.87B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 16.18B | 719.28M | 4.65% |
Dec 31, 2023 | 15.46B | 1.65B | 11.93% |
Dec 31, 2022 | 13.81B | 1.01B | 7.86% |
Dec 31, 2021 | 12.80B | 2.01B | 18.66% |
Dec 31, 2020 | 10.79B | -1.04B | -8.76% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Jiangsu Hengrui Medicine | 29.19B |
Shenzhen Mindray Bio-Medical Electronics | 35.59B |
WuXi AppTec | 39.59B |
Sichuan Biokin Pharmaceutical | 5.82B |
Zhangzhou Pientzehuang Pharmaceutical., | 10.76B |
Aier Eye Hospital Group | 21.81B |
Shanghai United Imaging Healthcare | 10.43B |
Yunnan Baiyao Group Co.,Ltd | 40.10B |